Mangoceuticals Inc (MGRX)

$0.77 0.00 (-0.61%)
Market Cap 10.71M
Revenue (ttm) 620,000.00
Net Income (ttm) -8.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,404.84%
Debt to Equity Ratio 0.00
Volume 180,600
Avg Vol 2,060,966
Day's Range N/A - N/A
Shares Out 13.91M
Stochastic %K 29%
Beta 2.56
Analysts Strong Buy
Price Target N/A

Company Profile

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone...

Industry: Health Information Services
Sector: Healthcare
Phone: 214 242 9619
Address:
15110 N. Dallas Parkway, Suite 600, Dallas, United States
2jmoney
2jmoney Dec. 26 at 2:31 PM
$MGRX 9:30 dart to the heart 😂
0 · Reply
TTT34
TTT34 Dec. 26 at 9:20 AM
$MGRX nothing has changed it seems. Still diluting and nothing to show for it
1 · Reply
OnionOptions
OnionOptions Dec. 25 at 9:33 AM
$MGRX Investor focus is migrating toward execution sequencing, because growth without leverage now attracts skepticism. Momentum turns durable only after multiple confirmations.
0 · Reply
Gest1010
Gest1010 Dec. 24 at 6:26 PM
$MGRX 4.25M Short Shares Availability.
1 · Reply
Justrise07
Justrise07 Dec. 24 at 4:51 PM
$MGRX 2pt $CTXR cover your loss
0 · Reply
Thralling
Thralling Dec. 24 at 3:58 PM
$MGRX Merry Christmas to all.
0 · Reply
modrica3
modrica3 Dec. 24 at 3:51 PM
$MGRX well pipe warrants cant be excersized cashlessly for 90 days so only way is at 1.42 per share , we will see what theyre deciding to do with it gl
1 · Reply
Kingjamesvii
Kingjamesvii Dec. 24 at 3:03 PM
$MGRX please sweet baby Jesus go back to 1.09.
1 · Reply
Sam201
Sam201 Dec. 24 at 2:42 PM
$MGRX on sidelines. Maybe 0.6 ish a good entry.
0 · Reply
LiquidityLama
LiquidityLama Dec. 24 at 9:59 AM
$MGRX Forward visibility remains uneven as resource allocation supports scalability without eroding optionality. Clear inflection points are required to justify renewed interest.
1 · Reply
Latest News on MGRX
Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements

Dec 19, 2025, 10:38 AM EST - 7 days ago

Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

Dec 19, 2025, 7:30 AM EST - 7 days ago

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules

Dec 18, 2025, 8:30 AM EST - 8 days ago

Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Nov 13, 2025, 7:37 PM EST - 6 weeks ago

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs

Nov 13, 2025, 2:04 PM EST - 6 weeks ago

Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs

LLY NVO

Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs

Nov 13, 2025, 7:15 AM EST - 6 weeks ago

Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs

LLY NVO

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

May 27, 2025, 9:00 AM EDT - 7 months ago

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market

Apr 28, 2025, 9:36 AM EDT - 8 months ago

ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market

CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Apr 26, 2025, 10:54 AM EDT - 8 months ago

CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Apr 25, 2025, 10:26 AM EDT - 8 months ago

ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Apr 25, 2025, 9:00 AM EDT - 8 months ago

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

Apr 22, 2025, 1:55 PM EDT - 8 months ago

CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Feb 3, 2025, 8:30 AM EST - 11 months ago

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Dec 19, 2024, 5:33 PM EST - 1 year ago

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Oct 21, 2024, 5:10 PM EDT - 1 year ago

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024

Oct 18, 2024, 8:45 AM EDT - 1 year ago

Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

Oct 11, 2024, 5:15 PM EDT - 1 year ago

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

Oct 3, 2024, 8:30 AM EDT - 1 year ago

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

Oct 1, 2024, 7:30 AM EDT - 1 year ago

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

Aug 15, 2024, 9:25 AM EDT - 1 year ago

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

Aug 9, 2024, 8:15 AM EDT - 1 year ago

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market

Aug 8, 2024, 8:30 AM EDT - 1 year ago

MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

Jul 24, 2024, 8:15 AM EDT - 1 year ago

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

Jul 16, 2024, 8:20 AM EDT - 1 year ago

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Jul 12, 2024, 1:30 PM EDT - 1 year ago

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets

Jul 11, 2024, 8:15 AM EDT - 1 year ago

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Jun 6, 2024, 8:30 AM EDT - 1 year ago

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

Jun 4, 2024, 4:00 PM EDT - 1 year ago

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

May 28, 2024, 8:30 AM EDT - 1 year ago

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

May 23, 2024, 8:30 AM EDT - 1 year ago

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

May 21, 2024, 8:30 AM EDT - 1 year ago

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

May 16, 2024, 4:40 PM EDT - 1 year ago

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

May 2, 2024, 8:00 AM EDT - 1 year ago

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

Apr 12, 2024, 8:45 AM EDT - 1 year ago

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment

Mar 12, 2024, 9:00 AM EDT - 1 year ago

MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment

MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth

Feb 20, 2024, 9:00 AM EST - 2 years ago

MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth

MANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE

Feb 6, 2024, 9:00 AM EST - 2 years ago

MANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Feb 5, 2024, 8:50 AM EST - 2 years ago

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

MangoRx's Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

Jan 19, 2024, 8:00 AM EST - 2 years ago

MangoRx's Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

Dec 15, 2023, 10:39 AM EST - 2 years ago

Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Dec 13, 2023, 7:30 AM EST - 2 years ago

MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT

Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America

Dec 6, 2023, 8:00 AM EST - 2 years ago

Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

Nov 29, 2023, 8:30 AM EST - 2 years ago

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Nov 16, 2023, 8:30 AM EST - 2 years ago

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men's Health Awareness Month

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men's Health Awareness Month

Mangoceuticals Launches TikTok Influencer Initiative and Becomes the Presenting Sponsor of the Only Stans Podcast with Glenny Balls

Oct 26, 2023, 7:30 AM EDT - 2 years ago

Mangoceuticals Launches TikTok Influencer Initiative and Becomes the Presenting Sponsor of the Only Stans Podcast with Glenny Balls

Mangoceuticals Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Bloomberg TV and Fox Business

Oct 13, 2023, 9:40 AM EDT - 2 years ago

Mangoceuticals Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Bloomberg TV and Fox Business

Mangoceuticals Announces the Official Launch of MangoRx Affiliate Marketing Program to Enhance and Accelerate Topline Growth

Oct 12, 2023, 9:15 AM EDT - 2 years ago

Mangoceuticals Announces the Official Launch of MangoRx Affiliate Marketing Program to Enhance and Accelerate Topline Growth

Mangoceuticals Launches New High-Production Quality Ad Providing Fresh Insight into its Proprietary Mango Erectile Dysfunction Pill Formula

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Mangoceuticals Launches New High-Production Quality Ad Providing Fresh Insight into its Proprietary Mango Erectile Dysfunction Pill Formula

2jmoney
2jmoney Dec. 26 at 2:31 PM
$MGRX 9:30 dart to the heart 😂
0 · Reply
TTT34
TTT34 Dec. 26 at 9:20 AM
$MGRX nothing has changed it seems. Still diluting and nothing to show for it
1 · Reply
OnionOptions
OnionOptions Dec. 25 at 9:33 AM
$MGRX Investor focus is migrating toward execution sequencing, because growth without leverage now attracts skepticism. Momentum turns durable only after multiple confirmations.
0 · Reply
Gest1010
Gest1010 Dec. 24 at 6:26 PM
$MGRX 4.25M Short Shares Availability.
1 · Reply
Justrise07
Justrise07 Dec. 24 at 4:51 PM
$MGRX 2pt $CTXR cover your loss
0 · Reply
Thralling
Thralling Dec. 24 at 3:58 PM
$MGRX Merry Christmas to all.
0 · Reply
modrica3
modrica3 Dec. 24 at 3:51 PM
$MGRX well pipe warrants cant be excersized cashlessly for 90 days so only way is at 1.42 per share , we will see what theyre deciding to do with it gl
1 · Reply
Kingjamesvii
Kingjamesvii Dec. 24 at 3:03 PM
$MGRX please sweet baby Jesus go back to 1.09.
1 · Reply
Sam201
Sam201 Dec. 24 at 2:42 PM
$MGRX on sidelines. Maybe 0.6 ish a good entry.
0 · Reply
LiquidityLama
LiquidityLama Dec. 24 at 9:59 AM
$MGRX Forward visibility remains uneven as resource allocation supports scalability without eroding optionality. Clear inflection points are required to justify renewed interest.
1 · Reply
Lrod0175
Lrod0175 Dec. 24 at 2:47 AM
$MGRX This profile is probably a bot. Easy block.
0 · Reply
Kingjamesvii
Kingjamesvii Dec. 23 at 9:02 PM
$MGRX was hoping Dman would bring something but... oh well
1 · Reply
2jmoney
2jmoney Dec. 23 at 8:14 PM
$MGRX idk why anyone speaking on a r/s that’s so far away- year minimum and Jacob is a pro at extensions for those. Gap filler play here
3 · Reply
modrica3
modrica3 Dec. 23 at 4:53 PM
$MGRX they can be excersized at any time at 1.42 , just cant be excersized cashlessly for 90 days and cashless excersize is whats unfavorable to shareholders
0 · Reply
Thralling
Thralling Dec. 23 at 4:26 PM
$MGRX well if it does RS and then doubles. I am good with that. Look at $DRUG they had a hard time getting going.
0 · Reply
max315
max315 Dec. 23 at 4:18 PM
$MGRX but they will also be converted post r/s and can be exercised then as well.
1 · Reply
max315
max315 Dec. 23 at 4:16 PM
$MGRX You guys are only here because the professor brought you here.
1 · Reply
Investor7952
Investor7952 Dec. 23 at 4:13 PM
$MGRX There trying to shake us out stand strong
0 · Reply
Njjd0208
Njjd0208 Dec. 23 at 4:08 PM
$MGRX this sucks
1 · Reply
Njjd0208
Njjd0208 Dec. 23 at 4:05 PM
$MGRX wtf..
0 · Reply
modrica3
modrica3 Dec. 23 at 2:58 PM
$MGRX offering just closed 1.93 millions shares at 1.295 per share and PIPE warrants to buy 1.93 millions shares at 1.42 per share good thing about PIPE warrants is that they can not be excersized cashlesly for at least 90 days so its either at 1.42 or none gl "2.4. Cashless Exercise Restriction. Notwithstanding anything herein to the contrary, the Holder shall not be permitted to effect a cashless exercise of this Warrant for a period of ninety (90) days following the Closing Date. Any attempted cashless exercise during such ninety (90)-day period shall be null and void and of no force or effect."
0 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 1:21 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Bounce potential $AZI - $RZLV - $FJET - $MGRX
0 · Reply